Skip to main content

Advertisement

SpringerLink
Log in

The immunobiology of myeloid-derived suppressor cells in cancer

  • Review
  • Published:
Tumor Biology

Abstract

The tumor microenvironment is a complex and heterogeneous milieu in which multiple interactions occur between tumor and host cells. Immunosuppressive cells which are present in this microenvironment, such as regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs), play an important role in tumor progression, via down-regulation of antitumor responses. MDSCs represent a heterogeneous group of cells originated from the myeloid lineage that are in the immature state. These cells markedly accumulate under pathologic conditions, such as cancer, infection, and inflammation, and use various mechanisms to inhibit both adaptive and innate immune responses. These immunosuppressive mechanisms include deprivation of T cells from essential amino acids, induction of oxidative stress, interference with viability and trafficking of T cells, induction of immunosuppressive cells, and finally polarizing immunity toward a tumor-promoting type 2 phenotype. In addition to suppression of antitumor immune responses, MDSCs can also enhance the tumor metastasis and angiogenesis. Previous studies have shown that increased frequency of MDSCs is related to the tumor progression. Moreover, various drugs that directly target these cells or reverse their suppressive activity can improve antitumor immune responses as well as increase the efficacy of immunotherapeutic intervention. In this review, we will first discuss on the immunobiology of MDSCs in an attempt to find the role of these cells in tumor progression and then discuss about therapeutic approaches to target these cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010;70:68–77.

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.

    Article  CAS  PubMed  Google Scholar 

  3. Jadidi-Niaragh F, Ghalamfarsa G, Memarian A, Asgarian-Omran H, Razavi SM, Sarrafnejad A, et al. Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia. Tumor Biol. 2013;34:929–40.

    Article  CAS  Google Scholar 

  4. Jadidi-Niaragh F, Ghalamfarsa G, Yousefi M, Tabrizi MH, Shokri F. Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions. Tumor Biol. 2013;34:2031–9.

    Article  CAS  Google Scholar 

  5. Jadidi-Niaragh F, Yousefi M, Memarian A, Hojjat-Farsangi M, Khoshnoodi J, Razavi SM, et al. Increased frequency of CD8+ and CD4+ regulatory T cells in chronic lymphocytic leukemia: association with disease progression. Cancer Investig. 2013;31:121–31.

    Article  CAS  Google Scholar 

  6. Namdar A, Mirzaei HR, Jadidi-Niaragh F, Ashourpour M, Ajami M, Hadjati J, et al. Multiple low doses of 5-fluorouracil diminishes immunosuppression by myeloid derived suppressor cells in murine melanoma model. Iran J Immunol. 2015;12:176.

    PubMed  Google Scholar 

  7. Butt A, Mills K. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2014;33:4623–31.

    Article  CAS  PubMed  Google Scholar 

  8. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59:1593–600.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Alizadeh D, Katsanis E, Larmonier N. Chemotherapeutic targeting of myeloid-derived suppressor cells. Oncoimmunology. 2014;3:e27359.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013;91:493–502.

    Article  CAS  PubMed  Google Scholar 

  11. Subiza JL, Vinuela JE, Rodriguez R, Gil J, Figueredo M, de la Concha EG. Development of splenic natural suppressor (NS) cells in Ehrlich tumor‐bearing mice. Int J Cancer. 1989;44:307–14.

    Article  CAS  PubMed  Google Scholar 

  12. Strober S. Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation: exploring obscure relationships. Annu Rev Immunol. 1984;2:219–37.

    Article  CAS  PubMed  Google Scholar 

  13. Slavin S, Strober S. Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR). J Immunol. 1979;123:942–6.

    CAS  PubMed  Google Scholar 

  14. Roder J, Duwe A, Bell D, Singhal S. Immunological senescence. I. The role of suppressor cells. Immunol. 1978;35:837.

    CAS  Google Scholar 

  15. Bennett JA, Rao VS, Mitchell MS. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc Natl Acad Sci. 1978;75:5142–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Duwe AK, Singhal SK. The immunoregulatory role of bone marrow: I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow. Cell Immunol. 1979;43:362–71.

    Article  CAS  PubMed  Google Scholar 

  17. Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol. 2010;199:273–81.

    Article  CAS  PubMed  Google Scholar 

  18. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Gabrilovich DI, Bronte V, Chen S-H, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yang R, Roden RB. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:426.

    Article  CAS  Google Scholar 

  21. Choi J, Suh B, Ahn Y-O, Kim TM, Lee J-O, Lee S-H, et al. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumor Biol. 2012;33:121–9.

    Article  CAS  Google Scholar 

  22. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32:19–25.

    Article  CAS  PubMed  Google Scholar 

  23. Yazdani Y, Mohammadnia-Afrouzi M, Yousefi M, Anvari E, Ghalamfarsa G, Hasannia H, et al. Myeloid-derived suppressor cells in B cell malignancies. Tumor Biol 2015:1–15.

  24. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8:618–31.

    Article  CAS  PubMed  Google Scholar 

  26. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood. 2003;102:2138–45.

    Article  CAS  PubMed  Google Scholar 

  27. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Investig. 2007;117:1155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bronte V, Serafini P, Apolloni E, Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 2001;24:431–46.

    Article  CAS  PubMed  Google Scholar 

  29. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941–52.

    Article  CAS  PubMed  Google Scholar 

  30. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol. 2011;11:802–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, et al. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1–dependent mechanism that is up-regulated by interleukin-13. Blood. 2010;116:5738–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989–99.

    Article  CAS  PubMed  Google Scholar 

  34. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 2008;181:5791–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hestdal K, Ruscetti F, Ihle J, Jacobsen S, Dubois C, Kopp W, et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol. 1991;147:22–8.

    CAS  PubMed  Google Scholar 

  36. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. Blood. 2008;111:4233–44.

    Article  CAS  PubMed  Google Scholar 

  38. Burke CF, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammation. Tumor Immunology and Immunotherapy 2014;95

  39. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13:721s–6.

    Article  CAS  PubMed  Google Scholar 

  40. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001;166:678–89.

    Article  CAS  PubMed  Google Scholar 

  41. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Investig. 2006;116:2777.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients’ CD4+ T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother. 2008;57:1493–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58:49–59.

    Article  CAS  PubMed  Google Scholar 

  44. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60:1419–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kübler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270–8.

    Article  CAS  PubMed  Google Scholar 

  46. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res. 2012;18:5212–23.

    Article  CAS  PubMed  Google Scholar 

  47. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182:5693–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, et al. IL4Rα + myeloid-derived suppressor cell expansion in cancer patients. J Immunol. 2009;182:6562–8.

    Article  CAS  PubMed  Google Scholar 

  49. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691–702.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor–based antitumor vaccine. J Clin Oncol. 2007;25:2546–53.

    Article  CAS  PubMed  Google Scholar 

  51. Oberlies J, Watzl C, Giese T, Luckner C, Kropf P, Müller I, et al. Regulation of NK cell function by human granulocyte arginase. J Immunol. 2009;182:5259–67.

    Article  CAS  PubMed  Google Scholar 

  52. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008;14:6674–82.

    Article  CAS  PubMed  Google Scholar 

  53. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fioravanti S, Manns MP, et al. S100A9 a new marker for monocytic human myeloid‐derived suppressor cells. Immunology. 2012;136:176–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+ CD25+ Foxp3+ T cells. Gastroenterology. 2008;135:234–43.

    Article  CAS  PubMed  Google Scholar 

  55. Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+ HLA‐DRlow/− monocytes in prostate cancer. Prostate. 2010;70:443–55.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005;65:3044–8.

    CAS  PubMed  Google Scholar 

  57. Liu C-Y, Wang Y-M, Wang C-L, Feng P-H, Ko H-W, Liu Y-H, et al. Population alterations of L-arginase-and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136:35–45.

    Article  CAS  PubMed  Google Scholar 

  58. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009;69:1553–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pak A, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young M. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34 (+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995;1:95–103.

    CAS  PubMed  Google Scholar 

  60. Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007;13:5243–8.

    Article  CAS  PubMed  Google Scholar 

  61. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev. 2008;222:162–79.

    Article  CAS  PubMed  Google Scholar 

  62. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175:4583–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol. 2003;170:270–8.

    Article  CAS  PubMed  Google Scholar 

  64. Terabe M, Matsui S, Park J-M, Mamura M, Noben-Trauth N, Donaldson DD, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte–mediated tumor immunosurveillance abrogation prevents tumor recurrence. J Exp Med. 2003;198:1741–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Merchav S, Apte R, Tatarsky I, Ber R. Effect of plasmacytoma cells on the production of granulocyte-macrophage colony-stimulating activity (GM-CSA) in the spleen of tumor-bearing mice. Exp Hematol. 1987;15:995–1000.

    CAS  PubMed  Google Scholar 

  66. Fu Y, Watson G, Jimenez JJ, Wang Y, Lopez DM. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res. 1990;50:227–34.

    CAS  PubMed  Google Scholar 

  67. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. 1999;162:5728–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337–43.

    Article  CAS  PubMed  Google Scholar 

  69. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo M, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18:226–32.

    Article  CAS  PubMed  Google Scholar 

  70. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al. Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF. Eur J Immunol. 2010;40:22–35.

    Article  CAS  PubMed  Google Scholar 

  71. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen S-H. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol. 2011;77:12–9.

    Article  PubMed  Google Scholar 

  73. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008;29:2035–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008;181:4666–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol. 2002;168:689–95.

    Article  CAS  PubMed  Google Scholar 

  77. Kusmartsev S, Gabrilovich DI. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother. 2002;51:293–8.

    Article  CAS  PubMed  Google Scholar 

  78. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol. 2005;174:4880–91.

    Article  CAS  PubMed  Google Scholar 

  79. Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol. 2005;174:636–45.

    Article  CAS  PubMed  Google Scholar 

  80. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2013;138:105–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn J-I, Cheng P, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Kutomi G, Tamura Y, Tanaka T, Kajiwara T, Kukita K, Ohmura T, et al. Human endoplasmic reticulum oxidoreductin 1‐α is a novel predictor for poor prognosis of breast cancer. Cancer Sci. 2013;104:1091–6.

    Article  CAS  PubMed  Google Scholar 

  83. Tanaka T, Kajiwara T, Torigoe T, Okamoto Y, Sato N, Tamura Y. Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding. J Immunol. 2015;194:2004–10.

    Article  CAS  PubMed  Google Scholar 

  84. Park S-J, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S-I, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol. 2004;173:3844–54.

    Article  CAS  PubMed  Google Scholar 

  85. Pan P-Y, Wang GX, Yin B, Ozao J, Ku T, Divino CM, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood. 2008;111:219–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Young MRI, Wright MA, Coogan M, Young ME, Bagash J. Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor β. Cancer Immunol Immunother. 1992;35:14–8.

    Article  CAS  PubMed  Google Scholar 

  87. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+ CD11b + myeloid cells that promote metastasis. Cancer Cell. 2008;13:23–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Youn JI, Gabrilovich DI. The biology of myeloid‐derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010;40:2969–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005;65:9525–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798–809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81:28–37.

    Article  CAS  PubMed  Google Scholar 

  92. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008;205:2235–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Farren MR, Carlson LM, Lee KP. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res. 2010;46:165–76.

    Article  CAS  PubMed  Google Scholar 

  94. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPβ transcription factor. Immunity. 2010;32:790–802.

    Article  CAS  PubMed  Google Scholar 

  95. Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller M, et al. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009;69:2506–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Munera V, Popovic PJ, Bryk J, Pribis J, Caba D, Matta BM, et al. Stat 6-dependent induction of myeloid derived suppressor cells after physical injury regulates nitric oxide response to endotoxin. Ann Surg. 2010;251:120–6.

    Article  PubMed  Google Scholar 

  98. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol. 2009;85:996–1004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202:931–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Shojaei F, Wu X, Zhong C, Yu L, Liang X-H, Yao J, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature. 2007;450:825–31.

    Article  CAS  PubMed  Google Scholar 

  101. LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A. 2004;101:16813–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008;111:5457–66.

    Article  CAS  PubMed  Google Scholar 

  103. Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, et al. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol. 2015;97:573–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Choudhury B, Srivastava S, Choudhury HH, Purkayastha A, DuttaGupta S, Ghosh SK. Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India. Tumor Biol. 2014;35:6739–48.

    Article  CAS  Google Scholar 

  105. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180–91.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839–49.

    Article  CAS  PubMed  Google Scholar 

  107. Rodriguez P, Zea A, Ochoa A. Mechanisms of tumor evasion from the immune response. Cancer Chemother Biol Response Modif. 2002;21:351–64.

    Article  Google Scholar 

  108. Rodríguez PC, Ochoa AC, editors. T cell dysfunction in cancer: role of myeloid cells and tumor cells regulating amino acid availability and oxidative stress. Semin Cancer Biol 2006. Academic Press.

  109. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity. 2005;22:633–42.

    Article  CAS  PubMed  Google Scholar 

  110. Gey A, Tadie JM, Caumont‐Prim A, Hauw‐Berlemont C, Cynober L, Fagon JY, et al. Granulocytic myeloid‐derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients. Clin Exp Immunol. 2015;180:280–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Gout P, Buckley A, Simms C, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x (c)-cystine transporter: a new action for an old drug. Leukemia. 2001;15:1633–40.

    Article  CAS  PubMed  Google Scholar 

  112. Ishii I, Akahoshi N, Yu X, Kobayashi Y, Namekata K, Komaki G, et al. Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J. 2004;381:113–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Mansoor MA, Svardal AM, Ueland PM. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem. 1992;200:218–29.

    Article  CAS  PubMed  Google Scholar 

  114. Arnér ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267:6102–9.

    Article  PubMed  Google Scholar 

  115. Bannai S. Transport of cystine and cysteine in mammalian cells. Biochimica et Biophysica Acta (BBA)-Reviews on. Biomembranes. 1984;779:289–306.

    CAS  Google Scholar 

  116. Sato H, Watanabe H, Ishii T, Bannai S. Neutral amino acid transport in mouse peritoneal macrophages. J Biol Chem. 1987;262:13015–9.

    CAS  PubMed  Google Scholar 

  117. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci. 2002;99:1491–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Castellani P, Angelini G, Delfino L, Matucci A, Rubartelli A. The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations. Eur J Immunol. 2008;38:2419–25.

    Article  CAS  PubMed  Google Scholar 

  119. Sakakura Y, Sato H, Shiiya A, Tamba M, Sagara J-I, Matsuda M, et al. Expression and function of cystine/glutamate transporter in neutrophils. J Leukoc Biol. 2007;81:974–82.

    Article  CAS  PubMed  Google Scholar 

  120. Zhang SM, Willett WC, Selhub J, Manson JE, Colditz GA, Hankinson SE. A prospective study of plasma total cysteine and risk of breast cancer. Cancer Epidemiol Biomark Prev. 2003;12:1188–93.

    CAS  Google Scholar 

  121. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9:1269–74.

    Article  CAS  PubMed  Google Scholar 

  122. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, et al. Indoleamine 2, 3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection. Int J Cancer. 2002;101:151–5.

    Article  CAS  PubMed  Google Scholar 

  123. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762–74.

    Article  CAS  PubMed  Google Scholar 

  124. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190:3783–97.

    Article  CAS  PubMed  Google Scholar 

  125. Fischer TA, Palmetshofer A, Gambaryan S, Butt E, Jassoy C, Walter U, et al. Activation of cGMP-dependent protein kinase Iβ inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells. J Biol Chem. 2001;276:5967–74.

    Article  CAS  PubMed  Google Scholar 

  126. Duhé RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci. 1998;95:126–31.

    Article  PubMed  PubMed Central  Google Scholar 

  127. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol. 1998;160:5729–34.

    CAS  PubMed  Google Scholar 

  128. Macphail SE, Gibney CA, Brooks BM, Booth CG, Flanagan BF, Coleman JW. Nitric oxide regulation of human peripheral blood mononuclear cells: critical time dependence and selectivity for cytokine versus chemokine expression. J Immunol. 2003;171:4809–15.

    Article  CAS  PubMed  Google Scholar 

  129. Gehad AE, Lichtman MK, Schmults CD, Teague JE, Calarese AW, Jiang Y, et al. Nitric oxide–producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas. J Investig Dermatol. 2012;132:2642–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res. 2011;71:5101–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Xia Y, Roman LJ, Masters BSS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem. 1998;273:22635–9.

    Article  CAS  PubMed  Google Scholar 

  132. Szabó C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007;6:662–80.

    Article  PubMed  CAS  Google Scholar 

  133. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci. 2004;101:4003–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Kusmartsev SA, Li Y, Chen S-H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol. 2000;165:779–85.

    Article  CAS  PubMed  Google Scholar 

  135. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 2003;24:301–5.

    Article  CAS  Google Scholar 

  136. Aulak KS, Miyagi M, Yan L, West KA, Massillon D, Crabb JW, et al. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci. 2001;98:12056–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Kono K, Salazar‐Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor‐derived macrophages down‐modulates signal‐transducing zeta molecules and inhibits tumor‐specific T cell‐and natural killer cell‐mediated cytotoxicity. Eur J Immunol. 1996;26:1308–13.

    Article  CAS  PubMed  Google Scholar 

  138. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc Natl Acad Sci. 2003;100:15035–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Li Y, Brazzell J, Herrera A, Walcheck B. ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding. Blood. 2006;108:2275–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Lorenzen I, Trad A, Grötzinger J. Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun. 2011;415:330–6.

    Article  CAS  PubMed  Google Scholar 

  141. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J Immunol. 2009;183:937–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208:1949–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Sakuishi K, Jayaraman P, Behar SM, Anderson AC, Kuchroo VK. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 2011;32:345–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol. 2012;24:213–6.

    Article  CAS  PubMed  Google Scholar 

  145. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008;68:2561–3.

    Article  CAS  PubMed  Google Scholar 

  146. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001;61:4756–60.

    CAS  PubMed  Google Scholar 

  147. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood. 2010;115:1461–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Nausch N, Galani IE, Schlecker E, Cerwenka A. Mononuclear myeloid-derived “suppressor” cells express RAE-1 and activate natural killer cells. Blood. 2008;112:4080–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Huang B, Pan P-Y, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006;66:1123–31.

    Article  CAS  PubMed  Google Scholar 

  150. Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma–associated Gr-1+ CD11b + myeloid cells. Cancer Res. 2006;66:6807–15.

    Article  CAS  PubMed  Google Scholar 

  151. Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68:5439–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009;70:325–30.

    Article  CAS  PubMed  Google Scholar 

  153. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977–83.

    Article  CAS  PubMed  Google Scholar 

  154. De Santo C, Salio M, Masri SH, Lee LY-H, Dong T, Speak AO, et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J Clin Invest. 2008;118:4036.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  155. Ko H-J, Lee J-M, Kim Y-J, Kim Y-S, Lee K-A, Kang C-Y. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J Immunol. 2009;182:1818–28.

    Article  CAS  PubMed  Google Scholar 

  156. Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13–regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 2005;65:11743–51.

    Article  CAS  PubMed  Google Scholar 

  157. Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med. 2005;202:1627–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11:6713–21.

    Article  CAS  PubMed  Google Scholar 

  159. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β1. J Immunol. 2009;182:240–9.

    Article  CAS  PubMed  Google Scholar 

  160. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood. 2007;109:4336–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Hu C-E, Gan J, Zhang R-D, Cheng Y-R, Huang G-J. Up-regulated myeloid-derived suppressor cell contributes to hepatocellular carcinoma development by impairing dendritic cell function. Scand J Gastroenterol. 2011;46:156–64.

    Article  CAS  PubMed  Google Scholar 

  162. Danelli L, Frossi B, Gri G, Mion F, Guarnotta C, Bongiovanni L, et al. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. Cancer Immunol Res. 2015;3:85–95.

    Article  CAS  PubMed  Google Scholar 

  163. Kitamura T, Qian B-Z, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015;15:73–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, et al. TGF-β receptor II loss promotes mammary carcinoma progression by Th17-dependent mechanisms. Cancer Discovery. 2011;1:430–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Condamine T, Ramachandran I, Youn J-I, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med. 2015;66:97–110.

    Article  CAS  PubMed  Google Scholar 

  166. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.

    Article  CAS  PubMed  Google Scholar 

  167. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284–90.

    Article  CAS  PubMed  Google Scholar 

  168. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, Dinarello CA, et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J Immunol. 2005;175:8200–8.

    Article  CAS  PubMed  Google Scholar 

  169. Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007;67:4507–13.

    Article  CAS  PubMed  Google Scholar 

  170. Haile LA, Von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, et al. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology. 2008;135:871–81. e5.

    Article  CAS  PubMed  Google Scholar 

  171. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol. 2000;164:2214–20.

    Article  CAS  PubMed  Google Scholar 

  172. Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006;66:9299–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Fujimura T, Mahnke K, Enk AH. Myeloid derived suppressor cells and their role in tolerance induction in cancer. J Dermatol Sci. 2010;59:1–6.

    Article  CAS  PubMed  Google Scholar 

  174. Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, et al. Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136:2352–60.

    Article  CAS  PubMed  Google Scholar 

  175. Huang H, Zhang G, Li G, Ma H, Zhang X. Circulating CD14+ HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumor Biol 2015:1–10.

  176. Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60:1269–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  177. OuYang L-Y, Wu X-J, Ye S-B, Zhang R-X, Li Z-L, Liao W, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med. 2015;13:47.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  178. Mundy-Bosse BL, Thornton LM, Yang H-C, Andersen BL, Carson WE. Psychological stress is associated with altered levels of myeloid-derived suppressor cells in breast cancer patients. Cell Immunol. 2011;270:80–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409–21.

    Article  CAS  PubMed  Google Scholar 

  180. Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong W-C, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS-Biol. 2011;9:1933.

    Article  CAS  Google Scholar 

  181. Shi Y, Ou L, Han S, Li M, Pena M, Pena E, et al. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis. 2014;3:e129.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  182. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, et al. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res. 2004;10:2709–19.

    Article  CAS  PubMed  Google Scholar 

  183. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011;30:2161–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.

    Article  CAS  PubMed  Google Scholar 

  185. Gracias DT, Katsikis PD. MicroRNAs: key components of immune regulation. Crossroads between Innate and Adaptive Immunity III: Springer; 2011. p. 15–26.

  186. O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010;10:111–22.

    Article  PubMed  CAS  Google Scholar 

  187. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol. 2012;188:5500–10.

    Article  CAS  PubMed  Google Scholar 

  188. Suzuki H, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene. 2014.

  189. Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang C-Y, et al. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol. 2014;192:1034–43.

    Article  CAS  PubMed  Google Scholar 

  190. Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, et al. MicroRNA‐155 deficiency enhances the recruitment and functions of myeloid‐derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer. 2015;136:E602–13.

    Article  CAS  PubMed  Google Scholar 

  191. Zhang M, Liu Q, Mi S, Liang X, Zhang Z, Su X, et al. Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol. 2011;186:4716–24.

    Article  CAS  PubMed  Google Scholar 

  192. Zhao JL, Rao DS, Boldin MP, Taganov KD, O’Connell RM, Baltimore D. NF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci. 2011;108:9184–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Liu Q, Zhang M, Jiang X, Zhang Z, Dai L, Min S, et al. miR‐223 suppresses differentiation of tumor‐induced CD11b + Gr1+ myeloid‐derived suppressor cells from bone marrow cells. Int J Cancer. 2011;129:2662–73.

    Article  CAS  PubMed  Google Scholar 

  194. Chen S, Zhang Y, Kuzel TM, Zhang B. Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs. Cancer cell & microenvironment. 2015;2.

  195. Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39:611–21.

    Article  CAS  PubMed  Google Scholar 

  196. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, et al. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR‐199a/125b and DNA methylation. EMBO Rep. 2012;13:1116–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  197. Curiel TJ. Regulatory T, cells and treatment of cancer. Curr Opin Immunol. 2008;20:241–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.

    Article  CAS  PubMed  Google Scholar 

  199. Pan W, Sun Q, Wang Y, Wang J, Cao S, Ren X. Highlights on mechanisms of drugs targeting MDSCs: providing a novel perspective on cancer treatment. Tumor Biol. 2015;36:3159–69.

    Article  CAS  Google Scholar 

  200. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007;67:11438–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Veltman J, Lambers ME, van Nimwegen M, Hendriks R, Hoogsteden H, Hegmans J, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer. 2010;103:629–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Fricke I, Mirza N, Dupont J, Lockhart C, Jackson A, Lee J-H, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res. 2007;13:4840–8.

    Article  CAS  PubMed  Google Scholar 

  203. Kusmartsev S, Eruslanov E, Kübler H, Tseng T, Sakai Y, Su Z, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol. 2008;181:346–53.

    Article  CAS  PubMed  Google Scholar 

  204. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009;15:2148–57.

    Article  CAS  PubMed  Google Scholar 

  205. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 2010;70:3526–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  206. van Cruijsen H, van der Veldt AA, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c + dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008;14:5884–92.

    Article  PubMed  CAS  Google Scholar 

  207. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian C-N, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 2010;70:1063–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  208. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Lathers DM, Clark JI, Achille NJ, Young MRI. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004;53:422–30.

    Article  CAS  PubMed  Google Scholar 

  210. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441–9.

    CAS  PubMed  Google Scholar 

  211. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 2010;10:464.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  212. Weed DT, Vella JL, Reis IM, Adriana C, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:39–48.

    Article  CAS  PubMed  Google Scholar 

  213. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A. 2005;102:4185–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  214. Ko H-J, Kim Y-J, Kim Y-S, Chang W-S, Ko S-Y, Chang S-Y, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 2007;67:7477–86.

    Article  CAS  PubMed  Google Scholar 

  215. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010;16:4583–94.

    Article  CAS  PubMed  Google Scholar 

  216. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–61.

    Article  CAS  PubMed  Google Scholar 

  217. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE. 2009;4:e7669.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  218. Shen XZ, Okwan-Duodu D, Blackwell W-L, Ong FS, Janjulia T, Bernstein EA, et al. Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells. Lab Investig. 2014;94:536–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  219. Lin C, Datta V, Okwan-Duodu D, Chen X, Fuchs S, Alsabeh R, et al. Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. 2011;25:1145–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  220. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67:11021–8.

    Article  CAS  PubMed  Google Scholar 

  221. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol. 2001;166:5398–406.

    Article  CAS  PubMed  Google Scholar 

  222. Hengesbach LM, Hoag KA. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr. 2004;134:2653–9.

    CAS  PubMed  Google Scholar 

  223. Zhao T, Du H, Ding X, Walls K, Yan C. Activation of mTOR pathway in myeloid-derived suppressor cells stimulates cancer cell proliferation and metastasis in lal−/− mice. Oncogene. 2015;34:1938–48.

    Article  CAS  PubMed  Google Scholar 

  224. Elleder M, Chlumská A, Hyánek J, Poupětová H, Ledvinová J, Maas S, et al. Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. J Hepatol. 2000;32:528–34.

    Article  CAS  PubMed  Google Scholar 

  225. Wu J, Zhang R, Tang N, Gong Z, Zhou J, Chen Y, et al. Dopamine inhibits the function of Gr-1+ CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J Leukoc Biol. 2015;97:191–200.

    Article  PubMed  CAS  Google Scholar 

  226. Zheng Y, Xu M, Li X, Jia J, Fan K, Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol. 2013;54:74–83.

    Article  CAS  PubMed  Google Scholar 

  227. Condamine T, Kumar V, Ramachandran IR, Youn J-I, Celis E, Finnberg N, et al. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014;124:2626.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Morteza Motallebnezhad, Elmira Safaie Qamsari, Salman Bagheri & Tohid Gharibi

  2. Immunology research center, Tabriz University of Medical Sciences, Tabriz, Iran

    Morteza Motallebnezhad, Elmira Safaie Qamsari, Salman Bagheri, Tohid Gharibi & Mehdi Yousefi

  3. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

    Morteza Motallebnezhad, Elmira Safaie Qamsari, Salman Bagheri, Tohid Gharibi & Mehdi Yousefi

  4. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    Farhad Jadidi-Niaragh

Authors
  1. Morteza Motallebnezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Farhad Jadidi-Niaragh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elmira Safaie Qamsari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salman Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tohid Gharibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mehdi Yousefi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mehdi Yousefi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Motallebnezhad, M., Jadidi-Niaragh, F., Qamsari, E.S. et al. The immunobiology of myeloid-derived suppressor cells in cancer. Tumor Biol. 37, 1387–1406 (2016). https://doi.org/10.1007/s13277-015-4477-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4477-9

Keywords

Search

Navigation